IL-10_NN
inhibits_VBZ
nuclear_JJ
factor-kappa_NN
B\/Rel_NN
nuclear_JJ
activity_NN
in_IN
CD3-stimulated_JJ
human_JJ
peripheral_JJ
T_NN
lymphocytes_NNS
._.

IL-10_NN
markedly_RB
reduces_VBZ
nuclear_JJ
factor_NN
-LRB-_-LRB-
NF_NN
-RRB-_-RRB-
-_:
kappa_NN
B\/Rel_NN
nuclear_JJ
activity_NN
induced_VBN
in_IN
PBMC_NN
by_IN
stimulation_NN
with_IN
the_DT
anti-CD3_JJ
mAb_NN
OKT3_NN
._.

The_DT
inhibition_NN
is_VBZ
exerted_VBN
specifically_RB
on_IN
the_DT
NF-kappa_NN
B\/Rel_NN
activation_NN
induced_VBN
by_IN
mAb_NN
OKT3_NN
,_,
and_CC
not_RB
that_DT
produced_VBD
by_IN
PMA_NN
._.

As_IN
judged_VBN
by_IN
supershifting_VBG
the_DT
DNA-protein_JJ
complexes_NNS
with_IN
Abs_NNS
recognizing_VBG
specific_JJ
components_NNS
of_IN
the_DT
NF-kappa_NN
B\/Rel_NN
protein_NN
family_NN
,_,
the_DT
p50\/p65_NN
-LRB-_-LRB-
Rel_NN
A_NN
-RRB-_-RRB-
heterodimeric_JJ
form_NN
of_IN
NF-kappa_NN
B_NN
is_VBZ
primarily_RB
affected_VBN
._.

The_DT
maximal_JJ
effect_NN
is_VBZ
observed_VBN
at_IN
the_DT
IL-10_NN
concentration_NN
of_IN
20_CD
U\/ml_NN
._.

IL-10_NN
inhibitory_JJ
activity_NN
is_VBZ
exerted_VBN
on_IN
T_NN
lymphocytes_NNS
and_CC
is_VBZ
mediated_VBN
by_IN
monocytes_NNS
._.

Indeed_RB
,_,
monocytes_NNS
pretreated_VBN
with_IN
IL-10_NN
are_VBP
able_JJ
so_IN
inhibit_VBP
NF-kappa_NN
B_NN
nuclear_JJ
activity_NN
in_IN
purified_VBN
T_NN
lymphocytes_NNS
stimulated_VBN
with_IN
OKT3_NN
._.

Soluble_JJ
factors_NNS
do_VBP
not_RB
appear_VB
to_TO
be_VB
involved_VBN
in_IN
the_DT
mechanism_NN
of_IN
inhibition_NN
._.

On_IN
the_DT
other_JJ
hand_NN
,_,
the_DT
up-regulation_NN
of_IN
CD80_NN
Ag_NN
,_,
found_VBN
on_IN
monocytes_NNS
obtained_VBN
from_IN
PBMC_NN
incubated_VBN
with_IN
OKT3_NN
,_,
is_VBZ
not_RB
detected_VBN
after_IN
addition_NN
of_IN
IL-10_NN
,_,
and_CC
the_DT
anti-CD28_JJ
mAb_NN
CLB-CD28_NN
\/_:
1_CD
restores_VBZ
the_DT
NF-kappa_NN
B\/Rel_NN
nuclear_JJ
activity_NN
in_IN
IL-10-inhibited_JJ
lymphocytes_NNS
._.

Therefore_RB
,_,
the_DT
NF-kappa_NN
B\/Rel_NN
inhibition_NN
might_MD
be_VB
ascribed_VBN
to_TO
a_DT
lack_NN
of_IN
cooperation_NN
between_IN
accessory_JJ
cells_NNS
and_CC
T_NN
lymphocytes_NNS
,_,
resulting_VBG
from_IN
down-regulation_NN
of_IN
a_DT
costimulatory_JJ
molecule_NN
,_,
such_JJ
as_IN
CD80_NN
,_,
produced_VBN
by_IN
IL-10_NN
on_IN
activated_VBN
monocytes_NNS
._.

Our_PRP$
results_NNS
demonstrate_VBP
that_IN
IL-10_NN
can_MD
inhibit_VB
the_DT
induction_NN
of_IN
NF-kappa_NN
B\/Rel_NN
nuclear_JJ
activity_NN
in_IN
CD3-stimulated_JJ
T_NN
lymphocytes_NNS
._.

Since_IN
inappropriate_JJ
activation_NN
of_IN
kappa_NN
B-driven_JJ
genes_NNS
has_VBZ
a_DT
physiopathologic_JJ
role_NN
in_IN
a_DT
number_NN
of_IN
diseases_NNS
,_,
such_JJ
as_IN
HIV_NN
infection_NN
,_,
our_PRP$
findings_NNS
support_VBP
the_DT
possibility_NN
of_IN
using_VBG
this_DT
cytokine_NN
to_TO
suppress_VB
an_DT
undesirable_JJ
activation_NN
of_IN
these_DT
transcription_NN
factors_NNS
._.

